CD4 and metabolic dysfunction-associated steatotic liver disease: In addition, using a methionine-choline-deficient (MCD) diet-induced NAFLD model, Ma et al. found that MitoTEMPO blockaded reactive oxygen species (ROS) production, reversed NAFLD-induced intrahepatic CD4+ T lymphocyte decrease, and finally delayed NAFLD-promoted hepatocarcinogenesis [16], indicating the potential therapeutic effects of MitoTEMPO on NAFLD.